In acute myeloid leukemia (AML), AML-derived mesenchymal stem cells (AML-MSCs) deliver METTL14 to leukemia cells via exosomes, where it stabilizes ROCK1 expression through the m6A-IGF2BP3 axis, thereby mediating radioresistance. This evidence concerns the gene METTL14 and acute myeloid leukemia.